100 Results for "

myelogenous leukemia

" in MedChemExpress (MCE) Product Catalog:
Products (100)

100 Results for "myelogenous leukemia" in MCE Product Catalog:

65
65 Publications Verification
Cat. No.: HY-112654
CAS No.: 2183470-12-2
Purity:  99.83%
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-15255
CAS No.: 167354-41-8
Purity:  99.90%
Synonyms: RS 33295-198; LY-335979
Target:  

P-glycoprotein

Research Areas:  

Cancer

Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-50671
CAS No.: 167465-36-3
Synonyms: RS 33295-198 trihydrochloride; LY-335979 trihydrochloride
Target:  

P-glycoprotein

Research Areas:  

Cancer

Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112852
CAS No.: 1315330-17-6
Purity:  98.47%
Target:  

Src Apoptosis

Research Areas:  

Cancer

TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-B1751B
CAS No.: 549-56-4
Quinidine sulfate is an antiarrhythmic agent. Quinidine sulfate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine sulfate is also a K + channel blocker with an IC50 of 19.9 μM. Quinidine sulfate can be used for malaria research .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10202
CAS No.: 387867-13-2
Purity:  99.48%
Synonyms: MLN518; CT53518
Target:  

FLT3 c-Kit PDGFR Apoptosis

Research Areas:  

Cancer

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10202A
CAS No.: 2438900-70-8
Purity:  99.78%
Synonyms: MLN518 hydrochloride; CT53518 hydrochloride
Target:  

FLT3 c-Kit PDGFR Apoptosis

Research Areas:  

Cancer

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15738
CAS No.: 778277-15-9
Purity:  99.95%
Target:  

Bcr-Abl

Research Areas:  

Cancer

GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13905
CAS No.: 895519-91-2
Purity:  99.80%
Synonyms: HHGV678 mesylate
Target:  

Bcr-Abl c-Kit PDGFR

Research Areas:  

Cancer

Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC50 values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-Y1103
CAS No.: 7782-63-0
Synonyms: Ferrous sulfate heptahydrate, 99%
Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-Y1103A
CAS No.: 7782-63-0
Synonyms: Ferrous sulfate heptahydrate, for cell culture, 99%
Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10943
CAS No.: 839706-07-9
Purity:  99.70%
Target:  

Bcr-Abl Ack1

Research Areas:  

Cancer

GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-Abl WT and Bcr-Abl T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109038
CAS No.: 509092-16-4
Synonyms: KRP-203 free base
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13660
CAS No.: 509088-69-1
Purity:  99.68%
Synonyms: KRP-203
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12475
CAS No.: 1355326-21-4
Purity:  99.43%
Synonyms: Agios 135
Research Areas:  

Cancer

Mutant IDH1-IN-1 (Agios 135) is a selective mutant IDH1 inhibitor with activity against both IDH1 R132H and IDH1 R132C. Mutant IDH1-IN-1 reduces the level of 2-hydroxyglutarate (2-HG), stabilizes mutant IDH1 protein, and restores blocked monocyte differentiation. Mutant IDH1-IN-1 can be used in tumor-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-125771
CAS No.: 19420-57-6
Purity:  99.53%
Synonyms: 18:0 Lyso-PC; LPC(18:0)
1-Stearoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine that inhibits HDAC3 activity and phosphorylation of STAT3 in K562 cells. 1-Stearoyl-sn-glycero-3-phosphocholine induces apoptosis and exhibits anticancer activity in chronic myelogenous leukemia (CML) K562 cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145723
CAS No.: 2070931-57-4
Purity:  97.04%
Target:  

FLT3 FGFR

Research Areas:  

Inflammation/Immunology Cancer

MAX-40279 is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 is also effective against the FLT3 mutants such as FLT3 D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 can be used for the research of acute myelogenous leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148602
CAS No.: 2813310-07-3
Purity:  99.99%
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Cancer

KH-4-43 is an inhibitor of E3 CRL4. KH-4-43 inhibits E3 CRL4's core ligase complex and exhibits anticancer activity. KH-4-43 has a binding Kd to E3 ROC1-CUL4A CTD or the highly related ROC1-CUL1 CTD at 83 nM or 9.4 μM, respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145723C
CAS No.: 2388506-44-1
Purity:  99.26%
Target:  

FLT3 FGFR

Research Areas:  

Inflammation/Immunology Cancer

MAX-40279 hemiadipate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate is also effective against the FLT3 mutants such as FLT3 D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemiadipate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemiadipate can be used for the research of acute myelogenous leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145723B
CAS No.: 2388506-43-0
Purity:  99.56%
Target:  

FLT3 FGFR

Research Areas:  

Inflammation/Immunology Cancer

MAX-40279 hemifumarate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate is also effective against the FLT3 mutants such as FLT3 D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemifumarate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemifumarate can be used for the research of acute myelogenous leukemia (AML) .
loading...
    loading...